Our data, based on a smaller cohort with a median follow-up of 3.5 years, showed for patients experiencing a pCR a numerical trend towards worse 3-year RFS in TNBC, cT3-4 or cN+ disease, though differences were not statistically significant.
← all excerpts
Impact of pathologic response and individual prognosis after neoadjuvant treatment in patients with early HER2+ and triple-negative breast cancer.
1
—
—